Immunogenicity of Two Efficacious Outer Membrane Protein-Based Serogroup B Meningococcal Vaccines among Young Adults in Iceland

• Published in: The Journal of Infectious Diseases
• Main Authors: Perkins, B. A., Jonsdottir, K., Briem, H., Griffiths, E., Plikaytis, B. D., Hoiby, E. A., Rosenqvist, E., Holst, J., Nokleby, H., Sotolongo, F., Sierra, G., Campa, H. C., Carlone, G. M., Williams, D., Dykes, J., Kapczynski, D., Tikhomirov, E., Wenger, J. D., Broome, C. V.
• Format: Text
• Language: English
• Published: Oxford University Press 1998
• Subjects: Major Articles; Iceland
• Online Access: http://jid.oxfordjournals.org/cgi/content/short/177/3/683; https://doi.org/10.1086/514232

Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as ⩾4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group ( P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.